The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...
"Ascites in decompensated cirrhosis is a poor prognostic indicator, with a 50% 2-year survival, worsening significantly to 20% to 50% at 1 year when the ascites becomes refractory to medical therapy." ...
ASCITES is a problem frequently encountered and often unsatisfactorily treated. An adjunct in the therapy of ascites has been tried in a limited number of cases and has seemed sufficiently helpful to ...
Use of RET inhibitors among patients with advanced NSCLC: A real-world evidence analysis. Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor ...
Bloating and ascites can both cause swelling and discomfort in your abdomen. Bloating is more common and usually goes away within hours to days. Ascites is more likely to be a sign of a serious ...
Paracentesis is a medical procedure that doctors perform to drain fluid from a person’s abdominal cavity. It is sometimes called an abdominal tap. Doctors refer to this buildup of fluid as ascites, ...
THE problem of the accumulation of fluid in the peritoneal cavity in association with cirrhosis of the liver has for many years presented a challenge to the surgeon, since it has always been tempting ...
Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of Advanced-stage Cancer Launch Offers Prolonged Puncture-free Survival and Delayed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback